SCHEMBL23710557

SCHEMBL23710557

SNCCCCCCNS

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.32
KDM4E B2RXH2 1/20 0.30
MAPK1 P28482 1/20 0.30
HIF1A Q16665 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18019067 0.82 EPHX1 (0.58) EPHX1
SCHEMBL2880657 0.82 EPHX1 (0.58) EPHX1
SCHEMBL21826470 0.82 EPHX1 (0.58) EPHX1
SCHEMBL24442991 0.82
SCHEMBL21826213 0.82 EPHX1 (0.58) EPHX1
SCHEMBL3793032 0.82
SCHEMBL21825580 0.82 EPHX1 (0.58) EPHX1
SCHEMBL23710556 0.82 ALOX15 (0.35)
SCHEMBL21066503 0.82 EPHX1 (0.58) EPHX1
SCHEMBL11742081 0.77 CYP2C19 (0.63) EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022103834-A1 COMBINATIONS OF METAP2 INHIBITORS AND CDK4/6 INHIBITORS FOR THE TREATMENT OF CANCER SYNDEVRX, INC. (US) 2022-05-19 WO disclosed
EP-3858385-A2 POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF Syndevrx, Inc. (US) 2021-08-04 EP disclosed